Readoutin 45d
Pfizer — RSVpreF
Phase 3 primary completion: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults..
- Date
- Jan 2027
- Type
- Readout
- Indication
- Lower Respiratory Tract Illness
Readoutin 45d
Phase 3 primary completion: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults..
The weekly brief is free. Pro adds reminders 7 days and 1 day before.